Absci/$ABSI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Absci
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Ticker
$ABSI
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
157
ISIN
US00091E1091
Website
Absci Metrics
BasicAdvanced
$348M
-
-$0.92
2.20
-
Price and volume
Market cap
$348M
Beta
2.2
52-week high
$6.33
52-week low
$2.01
Average daily volume
3.6M
Financial strength
Current ratio
5.717
Quick ratio
4.962
Long term debt to equity
2.357
Total debt to equity
4.486
Interest coverage (TTM)
-238.72%
Profitability
EBITDA (TTM)
-98.674
Gross margin (TTM)
-1,282.91%
Net profit margin (TTM)
-2,232.13%
Operating margin (TTM)
-2,320.23%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-27.53%
Return on equity (TTM)
-48.98%
Valuation
Price to revenue (TTM)
66.057
Price to book
1.75
Price to tangible book (TTM)
2.25
Price to free cash flow (TTM)
-4.141
Free cash flow yield (TTM)
-24.15%
Free cash flow per share (TTM)
-65.92%
Growth
Revenue change (TTM)
-9.95%
Earnings per share change (TTM)
-20.58%
3-year revenue growth (CAGR)
1.99%
3-year earnings per share growth (CAGR)
-19.64%
What the Analysts think about Absci
Analyst ratings (Buy, Hold, Sell) for Absci stock.
Bulls say / Bears say
Absci's collaboration with AstraZeneca has achieved a significant milestone by delivering AI-designed antibody sequences targeting oncology, potentially accelerating the development of new cancer treatments. (investing.com)
The company secured a $20 million strategic investment from AMD, enhancing its financial position and supporting further development of its AI Integrated Drug Creation platform. (stocktitan.net)
Absci's pipeline includes ABS-101, advancing toward Phase 1 clinical studies in the first half of 2025, and ABS-201, targeting androgenic alopecia, indicating progress in developing novel therapeutics. (stocktitan.net)
Absci reported a net loss of $29.0 million in Q4 2024 and a full-year net loss of $103.1 million, reflecting ongoing financial challenges. (stocktitan.net)
The company's Q4 2024 revenue was $0.7 million, indicating limited revenue generation despite strategic partnerships and investments. (stocktitan.net)
Absci's cash and investments totaled $112.4 million as of December 31, 2024, suggesting a need for careful financial management to sustain operations into the first half of 2027. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Absci Financial Performance
Revenues and expenses
Absci Earnings Performance
Company profitability
Absci News
AllArticlesVideos
Absci Appoints Biopharma Leader Mary Szela to Board of Directors
GlobeNewsWire·5 days ago
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results
GlobeNewsWire·2 months ago
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Absci stock?
Absci (ABSI) has a market cap of $348M as of July 12, 2025.
What is the P/E ratio for Absci stock?
The price to earnings (P/E) ratio for Absci (ABSI) stock is 0 as of July 12, 2025.
Does Absci stock pay dividends?
No, Absci (ABSI) stock does not pay dividends to its shareholders as of July 12, 2025.
When is the next Absci dividend payment date?
Absci (ABSI) stock does not pay dividends to its shareholders.
What is the beta indicator for Absci?
Absci (ABSI) has a beta rating of 2.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.